Eduardo Schenberg, Pharmacology Research & Perspectives Petrie-Flom Center Psychedelic Use, Law, and Spiritual Experience (PULSE) Affiliated Researcher Eduardo Schenberg writes about how the recent review of a new drug application for MDMA-assisted therapy for post traumatic stress disorder by the United States’ Food and Drug Administration (FDA) highlighted epistemological and methodological challenges for evidence assessments….
Fragile Gains, Persistent Setbacks: The Muddled Arc of American Drug-Law Reform
Ifetayo Harvey, The Yale Law Journal Forum Petrie-Flom Center Psychedelic Use, Law, and Spiritual Experience (PULSE) Affiliated Researcher Ifetayo Harvey analyzes the legal, social, and political dimensions of drug decriminalization in the context of current debates….
Separation of Drug Scheduling Powers
Mason Marks, Yale Law Journal Forum Petrie-Flom Center Senior Fellow Mason Marks writes how drug scheduling places substances believed to be harmful and addictive under strict federal control. In 1970, Congress enacted the Controlled Substances Act (CSA), which split drug scheduling authority between executive departments to leverage their specialized expertise. Today, the CSA grants the…
Legal battle rages over reopening a Detroit psychedelic mushroom-using church
The Detroit News // Petrie-Flom Center By Kara Berg, featuring Petrie-Flom Center Fellow in Psychedelic Law and Spirituality Victoria Litman…
Psychedelic Medicine Exceptionalism
I. Glenn Cohen and Mason Marks, The American Journal of Bioethics Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential,…
Focused Bodywork as Facilitated Communication: Cautionary Perspectives on Touch in Psychedelic Therapy
Neşe Devenot, The American Journal of Bioethics Project on Psychedelic Law and Regulation (POPLAR) affiliated researcher at the Petrie-Flom Center highlights ethical concerns about the practice of “focused bodywork” that was utilized in MDMA-assisted therapy clinical trials….
Would You Sell Your Ancestors? The ethical paradigms of Ayahuasca (Part II)
Bill of Health // Petrie-Flom Center Daiara Tukano and Maria Fernanda Gebara consider paths forward to true ethical engagement, following the Petrie-Flom Center’s Law and Policy of Psychedelic Medicine 2024 Annual Conference…
Would You Sell Your Ancestors? The ethical paradigms of Ayahuasca (Part I)
Bill of Health // Petrie-Flom Center Daiara Tukano and Maria Fernanda Gebara highlight the ethical considerations surrounding the use of Indigenous medicines, following the Petrie-Flom Center’s Law and Policy of Psychedelic Medicine 2024 Annual Conference…
Possible paths for drug reform?
Harvard Law Today // Petrie-Flom Center At a Petrie-Flom book talk, panelists discuss the lost history of constitutional challenges to punitive drug laws and possible ways forward…
Psychedelics, Psychosocial Support, and Psychotherapy: Why It Matters for the Law, Ethics, and Business of Medical Psychedelic Use
I. Glenn Cohen, Fordham Law Review This Essay, Part of a Symposium on Drug Law for the 21st Century, proceeds as follow. Part I briefly describes how vociferous this debate has become among advocates for the medical use of psychedelics. Part II discusses why this choice matters, legally and ethically. This includes a discussion of…